NOT KNOWN DETAILS ABOUT HEMGENIX

Quantity of eligible individuals: CDEC talked about the uncertainty in the quantity of clients with reasonably critical to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some people who're categorized as possessing gentle or moderate disease may have a severe bleedin